The benefits of Fab-scFv over full-length antibodies or other bispecific antibody formats include the ability to target two distinct antigens or epitopes at once, prevent light chain mispairing, increase half-life, activate or inhibit immune effector functions, and more effectively penetrate tumor tissues. It does, however, have certain drawbacks. For example, scFv fragments may lead to antibody denaturation or aggregation, and recombinant DNA or phage display technologies may entail high costs, inefficiencies, and other issues in addition to potential immunogenicity or toxicity reactions.